doi:10.1038/s41598-024-65310-y Neelakantan H, Hommel JD, Watowich SJ, et al
Using Tier 3 protocols when youre a Tier 1 candidate isnt more effective its inappropriate and potentially risky
Mendias stresses that when it comes to unapproved peptides, there's still a lot where we don't understand the safety profile. Whats Behind the Proposed Change OVER THE YEARS , the gray market for experimental peptides has ballooned, driven initially by bodybuilders looking for a competitive edge and then later by biohackers and people with unmet medical needs
Importantly, this proof-of-concept study showed that the relative abundance of Lactobacillus , a genus associated with weight loss 58 , was uniquely increased and Erysipelatoclostridium was distinctly decreased in mice given 5A-1MQ treatment and an LD switch compared to mice switched to LD and given vehicle treatment
These trials are proof enough that these peptides are active in the human body